Preventive Role of Erceflora (Bacillus clausii)
Erceflora (Bacillus clausii) has a limited but specific preventive role primarily for antibiotic-associated diarrhea (AAD) and Clostridioides difficile infection (CDI) prevention in patients receiving antibiotics, though it is NOT among the specifically recommended probiotic strains in the highest-quality guidelines.
Key Evidence Limitations
The 2020 AGA Clinical Practice Guidelines 1 provide the most authoritative framework for probiotic use but do not specifically recommend Bacillus clausii for any indication. Instead, the AGA conditionally suggests specific other probiotic strains for AAD/CDI prevention, including:
- Saccharomyces boulardii
- 2-strain combination: L. acidophilus CL1285 + L. casei LBC80R
- 3-strain combination: L. acidophilus, L. delbrueckii subsp bulgaricus, B. bifidum
- 4-strain combination of the above plus S. salivarius subsp thermophilus
This is a conditional recommendation with low-quality evidence 1.
Where Bacillus clausii May Have a Role
1. Prevention of Antibiotic-Associated Diarrhea
Recent systematic review evidence suggests B. clausii (O/C, N/R, SIN, T strains) may reduce AAD risk 2:
- Dosing: 4 × 10⁹ CFU/day for children; 6 × 10⁹ CFU/day for adolescents and adults
- Duration: Up to 14 days during antibiotic therapy
- Reduces gastrointestinal symptoms including diarrhea, nausea, and epigastric pain
A 2025 Cochrane review 3 found probiotics generally may reduce CDAD with an absolute risk reduction of 1.6% (NNT = 65), though this pooled various probiotic strains, not specifically B. clausii.
2. Geographic Considerations
Asian expert consensus 4 recommends B. clausii as:
- Adjunct treatment with oral rehydration solution for acute viral diarrhea
- Consideration for prevention of AAD and C. difficile-induced diarrhea
- Adjunct treatment for Helicobacter pylori eradication
However, this reflects regional practice patterns rather than high-quality evidence.
Important Caveats and Safety Concerns
Do NOT Use In:
- Severely ill or immunocompromised patients 1 - the AGA specifically notes patients who place high value on avoiding potential harms should reasonably select no probiotics
- Children with acute gastroenteritis in North America 1 - the AGA conditionally suggests AGAINST probiotic use (conditional recommendation, moderate-quality evidence)
- A 2025 case report 5 documented Alkalihalobacillus clausii bacteremia in an 87-year-old man treated with B. clausii for acute diarrhea, resulting in septic shock
Limited Evidence For:
- A 2022 Indian RCT 6 showed no significant difference between B. clausii and placebo for acute diarrhea in children when added to standard ORT and zinc
- A 2015 RCT 7 found B. clausii did NOT reduce late-onset sepsis in preterm infants
Practical Recommendations
If choosing to use B. clausii for AAD prevention:
- Start concurrently with antibiotic therapy
- Children: 4 × 10⁹ CFU/day (typically 1 vial twice daily)
- Adults: 6 × 10⁹ CFU/day (typically 1 vial 2-3 times daily)
- Continue throughout antibiotic course and up to 14 days total
- Avoid in immunocompromised, critically ill, or those with central venous catheters
However, if evidence-based practice is the priority, consider using one of the AGA-recommended probiotic strains listed above instead 1, as these have stronger guideline support despite still being conditional recommendations with low-quality evidence.
Cost-benefit consideration: Patients who place high value on avoiding costs or have low baseline risk of CDI (outpatient setting, < 2% risk) may reasonably decline any probiotic prophylaxis 1.
The evidence for B. clausii remains substantially weaker than for other probiotic strains, and its use should be considered second-line when guideline-recommended probiotics are unavailable or unaffordable.